Manufactures pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and Xanthine derivatives at facilities including Tarapur in Maharashtra. Operates a CDMO/CMO business that recorded its highest-ever quarterly revenue of Rs. 155 crore in Q4 FY26. A new manufacturing block at Tarapur Unit 5 adds 3,600 TPA of Xanthine derivatives capacity, taking total Xanthine capacity to 9,600 TPA. Plans to begin R&D investment in peptides and oligonucleotides (TIDES) in FY27 and is building a dedicated CDMO block at Atali with a one-year completion target. Capex was approximately Rs. 400 crore in FY26, with similar levels guided for FY27. Materials make up 45.6% of revenue, the largest cost component, followed by other operating expenses at 24.3% and employee cost at 9.5%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. APIs and Intermediates, Xanthine derivatives, CDMO/CMO services. Asset-heavy pharmaceutical manufacturing with a mix of API/intermediate production, specialty Xanthine derivatives, and CDMO services.
| ₹ crore · consolidated | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 1,945 | 1,853 | 2,115 | 1,819 |
| EBITDA (ex other income) | 342 | 386 | 464 | 366 |
| margin % | 17.6 | 20.8 | 22.0 | 20.1 |
| Owners' profit | 193 | 216 | 272 | 173 |
| EPS, as reported (₹) | 21.35 | 23.93 | 30.06 | 19.27 |
| ROE % · ROCE % | 12.4 · 17.2 | 12.3 · 16.8 | 13.7 · 17.2 | 8.2 · 10.7 |
| Debt / equity (x) | 0.14 | 0.15 | 0.20 | 0.32 |
| Cash from operations | 263 | 216 | 332 | 262 |
| Capex | (120) | (156) | (402) | (409) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 |
| Profit before tax | 72 | 101 | 115 | 67 | 39 | 58 | 76 | 94 |
| Net profit | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 |
| EPS (₹) | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.40 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Stamp authority orders Rs 59.5 Cr duty and penalty on 2022 demerger; company to challenge | regulatory legal | high | — | — |
| 31 Aug 2026 · Sr. Management Personnel resignation at Aarti Pharmalabs | management changes | medium | — | — |
| 30 Aug 2026 · 7th AGM on September 22, 2026 via video conferencing; annual report dispatched | compliance | minimal | — | — |
| 29 Aug 2026 · Aarti Pharmalabs submits BRSR for FY 2025-26 | compliance | medium | — | — |
| 29 Aug 2026 · 7th AGM notice on Sep 22, 2026 via video conferencing; FY26 annual report attached | board shareholder meetings | medium | — | — |
| 29 Aug 2026 · Notice of 7th AGM and Annual Report for FY 2025-26 | board shareholder meetings | low | — | — |
| 18 Aug 2026 · AGM on Sep 22, 2026 via video conferencing; final dividend record date Sep 15 | compliance | minimal | — | — |
| 17 Aug 2026 · Record Date Set for Final Dividend FY 2025-26 | corporate actions | high | — | — |
| 17 Aug 2026 · Q1 FY27: Revenue up 42% at INR 535 cr, EBITDA margin 25.4% | investor communications | medium | — | — |
| 10 Aug 2026 · Q1 FY27 Earnings Call Recording Now Available on Website | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 35.2 | 28.9 | 98 of 169 | 42% |
| P/B | 3.5 | 3.3 | 90 of 163 | 45% |
| ROCE | 8.8 | 10.8 | 107 of 183 | 42% |
| ROE | 8.2 | 10.4 | 100 of 171 | 42% |
| Debt / Equity | 0.3 | 0.1 | 122 of 171 | 29% |
| EBITDA margin | 25.5 | 17.5 | 50 of 165 | 70% |
| Revenue growth | 38.7 | 16.3 | 28 of 161 | 83% |
| Profit growth | 53.8 | 30.9 | 62 of 158 | 61% |
| Market cap | 7511 | 839 | 48 of 182 | 74% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
